Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments

NCT02695121 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02695121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02695121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 1, 2017
Completion date
January 30, 2025
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer